PLEGRIDY (peginterferon beta-1a), disease modifying therapy for multiple sclerosis

No clinical benefit demonstrated in the treatment of the relapsing-remitting multiple sclerosis (RRMS) compared with existing treatments

• PLEGRIDY has a Marketing Authorisation in the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
• It is an alternative to other first-line disease modifying therapies indicated in RRMS.
• Its efficacy versus placebo has been demonstrated. PLEGRIDY, administered subcutaneously once every 2 weeks, has not shown any clinical added value compared with available therapies.